NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 148)
Posted On: 08/08/2019 3:44:14 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Completes Initial R&D Program with the National Research Council of Canada
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced successful completion of its Master Collaborative Research Agreement (“the R&D Program”) with the National Research Council of Canada (“NRC”). The R&D program sought to investigate technical aspects and new opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions using Lexaria’s patented DehydraTECH(TM) technology with a primary goal to determine whether, through its processing, DehydraTECH causes the formation of a new molecular entity (“NME”). According to the update, all evidence aligns to confirm that no covalent-bonded NME is created with Lexaria’s technology. Processes or technologies that do create an NME, including certain forms of nanotechnology, often face much more extensive regulatory hurdles from agencies, such as the FDA or Health Canada, to prove that the NME is safe for human consumption.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced successful completion of its Master Collaborative Research Agreement (“the R&D Program”) with the National Research Council of Canada (“NRC”). The R&D program sought to investigate technical aspects and new opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions using Lexaria’s patented DehydraTECH(TM) technology with a primary goal to determine whether, through its processing, DehydraTECH causes the formation of a new molecular entity (“NME”). According to the update, all evidence aligns to confirm that no covalent-bonded NME is created with Lexaria’s technology. Processes or technologies that do create an NME, including certain forms of nanotechnology, often face much more extensive regulatory hurdles from agencies, such as the FDA or Health Canada, to prove that the NME is safe for human consumption.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼